H.R. 4392 — Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025

This section directs the Secretary of Health and Human Services to (1) conduct or support research on increasing early detection of, and intervention for, uterine fibroids and (2) formulate evidence-based or evidence-informed strategies to increase early detection in health care settings based on such research and other relevant information. The Secretary must finalize these strategies as expeditiously as possible to make them available to grantees under section 3.

This section authorizes the Secretary of Health and Human Services to award grants to states for programs to increase early detection of and intervention for uterine fibroids and to develop and implement public awareness and education campaigns on early detection and intervention. Grant funds may be used for (1) screening procedures, including advanced gynecological imaging (and payment therefor); (2) patient navigation services; (3) implementation of evidence-based or evidence-informed strategies to increase early detection in health care settings; and (4) facilitating access to health care settings. In awarding grants, the Secretary must give priority to states proposing programs in geographic areas with socially vulnerable populations at elevated risk of uterine fibroid development.

This section authorizes the Secretary to award grants for research, which may include clinical trials, related to (1) disparities in pain control and management in uterine fibroid surgical treatment; or (2) Asherman’s Syndrome, intrauterine adhesions, and other intrauterine conditions as determined appropriate by the Secretary.

This section requires the Secretary of HHS to submit to Congress, and make publicly available on the HHS website, a report not later than two years after the initial award of grants under this Act—and biennially thereafter—summarizing the findings and results of programs and activities funded through those grants. The section further requires the Secretary to submit to Congress, and make publicly available on the HHS website, a report not later than two years after enactment—and biennially thereafter—outlining research developments and findings related to (1) disparities in pain control and management in uterine fibroid surgical treatment and (2) Asherman’s Syndrome, intrauterine adhesions, and other intrauterine conditions as determined appropriate by the Secretary.